ClinicalTrials.gg
CompletedNCT03420742Updated Jan 27, 2023Results posted

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

A Phase 1 interventional study of Midazolam and Brigatinib in Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors, sponsored by Takeda. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-27.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Carcinoma with a site in Italy — 13 open to participants now, 25 under way, 13 of them phase 3. Carcinoma · Italy.

Enrollment
65th of 67
24 · median 245
Started
2019
with 4 others
Phase 1
2 of 71
none open now
Registered
38th of 71
by date

Among the 71 studies in Carcinoma with a site in Italy, this one is the 65th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2019, is one of 2 in phase 1, and was the 38th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

13 of the 71 studies in Carcinoma with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.

Read the detailed description

The study will enroll approximately 20 participants to achieve approximately 15 PK-evaluable participants for assessment. This study will consist of 2 parts: Part A of the study will evaluate the effect of repeat-dose administration of brigatinib on the single-dose PK of midazolam. Part B of the study is exploratory and will allow participants to continue brigatinib until disease progression (PD). All participants will receive study drug via the oral route. Participants will be assigned to: Midazolam 3 mg + Brigatinib 90 mg.

The overall time to participate in this study is 26 months. Participants will have a 28-day PK cycle in Part A and a maximum of 23 cycles in Part B, and a 30-day follow-up period after end of treatment.

03

Conditions studied

  • Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Keywords

  • Drug therapy, brigatinib, lung cancer, ALK, ROS1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Locally advanced or solid tumors who meet 1 of the following 4 criteria:

    • With locally advanced or metastatic ALK-positive NSCLC who have progressed on or are intolerant to treatment with at least 1 other ALK inhibitor.
    • With ALK-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.
    • With locally advanced or metastatic ROS1-positive NSCLC who have progressed on crizotinib therapy or are intolerant to crizotinib, or
    • With ROS1-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.
  2. (ECOG) performance status of 0 or 1.
  3. Have at least 1 target lesion per (RECIST) version 1.1.
  4. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI CTCAE) version 4.03 Grade less than or equal to (\<=) 1.
  5. Suitable venous access for study-required blood sampling (that is, including PK and laboratory safety tests).

Exclusion criteria

Exclusion Criteria:

  1. Systemic treatment with strong or moderate cytochrome P450 3A () inhibitors or inducers within 14 days before enrollment.
  2. Prior therapy with brigatinib.
  3. Received prior ALK-inhibitor therapy within 7 days before the first dose of study drug.
  4. Treatment with any systemic anticancer agents within 14 days or 5 half-lives, whichever is longer, before the first dose of study drug.
  5. Received chemotherapy or radiation therapy within 14 days before the first dose of study drug, except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy.
  6. Received antineoplastic monoclonal antibodies within 30 days before the first dose of study drug.
  7. Had major surgery within 30 days before the first dose of study drug. Minor surgical procedures, such as catheter placement or minimally invasive , are allowed.
  8. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with and without cord compression are allowed.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Midazolam 3 mg + Brigatinib 90 mg

    Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

    Drug: Midazolam · Drug: Brigatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam

    The statistical analysis was calculated via a mixed-effects analysis of variance (ANOVA) fitting terms for treatment (midazolam with or without brigatinib coadministration).

    Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)

  2. Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam

    The statistical analysis was calculated via a mixed-effects ANOVA fitting terms for treatment (midazolam with or without brigatinib coadministration).

    Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)

  3. Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam

    Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)

07

Results

Posted Jan 27, 2023

Participant flow

Participants took part in the study at 10 investigative sites in the Netherlands, Italy, and Spain from 26 June 2019 to 29 April 2021.

Part A (Cycle 1)
Participant flow — Part A (Cycle 1)
MilestoneParts A and B: All Participants
Started24
Completed24
Not completed0
Part B (Cycle 2 to Cycle 20)
Participant flow — Part B (Cycle 2 to Cycle 20)
MilestoneParts A and B: All Participants
Started22
Completed22
Not completed0

Outcome measures

PrimaryPart A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam

The statistical analysis was calculated via a mixed-effects analysis of variance (ANOVA) fitting terms for treatment (midazolam with or without brigatinib coadministration).

Time frame:
Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam
hour*nanogram per milliliter (h*ng/mL)Part A, Cycle 1 Day 1: Midazolam AlonePart A, Cycle 1 Day 21: Midazolam + Brigatinib
Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam57.2 ± 30.342.1 ± 54.2
Statistical analysis
  • Part A, Cycle 1 Day 1: Midazolam Alone vs Part A, Cycle 1 Day 21: Midazolam + Brigatinib · Geometric least squares mean ratio: 0.741 · 90% CI 0.600 to 0.915The ratios of geometric mean were calculated on the basis of the within-participant variance. Participant was treated as a random effect in the model.
PrimaryPart A, Cmax: Maximum Observed Plasma Concentration for Midazolam

The statistical analysis was calculated via a mixed-effects ANOVA fitting terms for treatment (midazolam with or without brigatinib coadministration).

Time frame:
Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam
nanogram per milliliter (ng/mL)Part A, Cycle 1 Day 1: Midazolam AlonePart A, Cycle 1 Day 21: Midazolam + Brigatinib
Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam19.7 ± 42.616.5 ± 49.9
Statistical analysis
  • Part A, Cycle 1 Day 1: Midazolam Alone vs Part A, Cycle 1 Day 21: Midazolam + Brigatinib · Geometric least squares mean ratio: 0.836 · 90% CI 0.662 to 1.06The ratios of geometric mean were calculated on the basis of the within-participant variance. Participant was treated as a random effect in the model.
PrimaryPart A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam
Time frame:
Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Reported as:
Median · hour
Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam
hourPart A, Cycle 1 Day 1: Midazolam AlonePart A, Cycle 1 Day 21: Midazolam + Brigatinib
Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam0.500 (0.220 to 1.93)0.500 (0.250 to 1.00)

Adverse events

Collected over Treatment-emergent adverse events were adverse events (AEs) that started from the first dose of the study drug up to 30 days after the last dose of the study drug (up to Cycle 20 Day 30 ) (Cycle length =28 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Parts A and B: All Participants8/24 (33.3%)17/24 (70.8%)23/24 (95.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventParts A and B: All Participants
DyspnoeaRespiratory, thoracic and mediastinal disorders3/24
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/24
Disease progressionGeneral disorders2/24
PneumoniaInfections and infestations2/24
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/24
Bile duct obstructionHepatobiliary disorders1/24
COVID-19Infections and infestations1/24
Confusional statePsychiatric disorders1/24
HaematuriaRenal and urinary disorders1/24
InfectionInfections and infestations1/24
Most frequent other events
Showing 10 of 30
Most frequent other events
EventParts A and B: All Participants
Blood creatine phosphokinase increasedInvestigations11/24
NauseaGastrointestinal disorders11/24
DiarrhoeaGastrointestinal disorders9/24
Aspartate aminotransferase increasedInvestigations8/24
DyspnoeaRespiratory, thoracic and mediastinal disorders8/24
Alanine aminotransferase increasedInvestigations7/24
AnaemiaBlood and lymphatic system disorders7/24
VomitingGastrointestinal disorders7/24
CoughRespiratory, thoracic and mediastinal disorders6/24
Lipase increasedInvestigations6/24

Baseline characteristics

Safety population consisted of all participants who received at least 1 dose of any study drug (brigatinib or midazolam).

Race (NIH/OMB)
Race (NIH/OMB)(Participants)Parts A and B: All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White23
More than one race0
Unknown or Not Reported1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Parts A and B: All Participants
Hispanic or Latino2
Not Hispanic or Latino21
Unknown or Not Reported1
Age, Continuous
Age, Continuous(years)Parts A and B: All Participants
Mean56.0 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Parts A and B: All Participants
Female13
Male11
Region of Enrollment
Region of Enrollment(Participants)Parts A and B: All Participants
Italy11
Netherlands2
Spain11
Estimated Glomerular Filtration Rate (eGFR)
Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73 m^2)Parts A and B: All Participants
Mean97.94 ± 40.596
Height
Height(centimeter (cm))Parts A and B: All Participants
Mean168.7 ± 9.64
Weight
Weight(kilogram (kg))Parts A and B: All Participants
Mean73.82 ± 22.415
08

Study locations

14 sites
  • Groupe Hospitalier Bichat-Claude Bernard - Hopital Bichat
    Paris, Ile-de-france 75018, France
  • Hopital de la Timone
    Marseille, Provence Alpes COTE D'azur 13005, France
  • Centro di Riferimento Oncologico di Aviano
    Aviano, Pordenone 33081, Italy
  • Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, 43126, Italy
  • Ospedale Santa Maria delle Croci
    Ravenna, 48121, Italy
  • Netherlands Cancer Institute
    Amsterdam, Noord-holland 1066 CX, Netherlands
  • Hospital Universitario Dexeus
    Barcelona, 8028, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • HM Centro Integral Oncologico Clara Campal
    Madrid, 28050, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2020, 8 months.

Results were first posted in Jan 2023, 2 years 10 months after primary completion.

Of 41 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's 8 months is below that.

Counting every sponsor, half of 70 studies reached it within 46 months; a quarter within 30 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 5, 2018
StartActual
Jun 26, 2019
Primary completionActual
Mar 24, 2020
CompletionActual
Apr 29, 2021
Results first posted
Jan 27, 2023
Last update
Jan 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03420742
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Jun 26, 2019
Primary completion
Mar 24, 2020
Completion
Apr 29, 2021
Results posted
Jan 27, 2023
Last update
Jan 27, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Brigatinib

Start the discussion